MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Stock List・Gossamer Bio Inc

Gossamer Bio Inc

Closed

SectorHealthcare

0.37 5.71

Buy Sell

Overview

Share price change

24h

Current

Min

0.36

Max

0.38

Key metrics
By Trading Economics
Income	983K -47M
Sales	505K 14M
Profit margin	-342.329
Employees	161
EBITDA	-346K -46M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+1089.19% upside

Dividends
By Dow Jones
Next Earnings	14 May 2026

Market Stats
By TradingEconomics
Market Cap	-30M 75M
Previous open	-5.34
Previous close	0.37

News Sentiment

By Acuity

97%

331 / 349 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

1.06 / 1.23 Support & Resistance

Gossamer Bio Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Apr 2026, 04:27 UTC

Major News Events

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 Apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2026, 18:30 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 Apr 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 Apr 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 Apr 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 Apr 2026, 16:50 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 Apr 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2026, 16:12 UTC

Earnings

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 Apr 2026, 15:56 UTC

Market Talk

Major News Events

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 Apr 2026, 15:56 UTC

Market Talk

Major News Events

Global Equities Roundup: Market Talk

3 Apr 2026, 15:56 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

3 Apr 2026, 15:20 UTC

Major News Events

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 Apr 2026, 15:08 UTC

Acquisitions, Mergers, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 Apr 2026, 14:11 UTC

Market Talk

Major News Events

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 Apr 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 Apr 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Apr 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 Apr 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 Apr 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 Apr 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Apr 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 Apr 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Apr 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 Apr 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 Apr 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 Apr 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 Apr 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 Apr 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer Comparison

Price change

Gossamer Bio Inc Forecast

Price Target

By TipRanks

1089.19% upside

12 Months Forecast

Average 4.4 USD 1089.19%

High 15 USD

Low 0.3 USD

Based on 9 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Gossamer Bio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.06 / 1.23Support & Resistance

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

331 / 349 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.